We are live on
!
Find out more
MAM
Melqart Asset Management Portfolio holdings
AUM
$1.01B
1-Year Est. Return
84.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.37%
1 Year Est. Return
+84.85%
3 Year Est. Return
+183.09%
5 Year Est. Return
+319.83%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
-$103M
(-8.5%)
Cap. Flow
-$144M
Cap. Flow
% of AUM
-13%
Top 10 Holdings %
Top 10 Hldgs %
55.09%
Holding
68
New
14
Increased
10
Reduced
27
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTLT
CATALENT, INC.
CTLT
|
+$37.4M |
| 2 |
SW
Smurfit Westrock
SW
|
+$32.8M |
| 3 |
HCP
HashiCorp, Inc. Class A Common Stock
HCP
|
+$28.1M |
| 4 |
HES
Hess
HES
|
+$16.6M |
| 5 |
SMAR
Smartsheet Inc.
SMAR
|
+$15.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$44.9M |
| 2 |
Cytokinetics
CYTK
|
+$25.8M |
| 3 |
Amazon
AMZN
|
+$20.9M |
| 4 |
Marvell Technology
MRVL
|
+$19.8M |
| 5 |
X
US Steel
X
|
+$16.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.77% |
| 2 | Healthcare | 20.23% |
| 3 | Consumer Discretionary | 12.17% |
| 4 | Energy | 8.8% |
| 5 | Industrials | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Indivior Pharmaceuticals
INDV
$4.58B
| $132K | 0.01% |
+13,510
| New | +$158K |
|
52
CALL
Alnylam Pharmaceuticals
ALNY
$29.3B
| – | – |
-13,500
| Closed | -$3.28M |
|
|
53
PUT
Alnylam Pharmaceuticals
ALNY
$29.3B
| – | – |
-13,500
| Closed | -$3.28M |
|
|
54
Amazon
AMZN
$2.96T
| – | – |
-108,036
| Closed | -$20.9M |
|
55
BioMarin Pharmaceuticals
BMRN
$12.4B
| – | – |
-172,949
| Closed | -$14.2M |
|
56
EPAM Systems
EPAM
$5.03B
| – | – |
-23,471
| Closed | -$4.42M |
|
57
Structure Therapeutics
GPCR
$3.78B
| – | – |
-92,335
| Closed | -$3.63M |
|
58
GitLab
GTLB
$6.58B
| – | – |
-92,614
| Closed | -$4.6M |
|
59
Hewlett Packard
HPE
$70.5B
| – | – |
-316,193
| Closed | -$6.69M |
|
60
IBM
IBM
$224B
| – | – |
-23,078
| Closed | -$3.99M |
|
61
MongoDB
MDB
$32.1B
| – | – |
-26,438
| Closed | -$6.61M |
|
62
PUT
Invesco S&P 500 Equal Weight ETF
RSP
$99.1B
| – | – |
-618,000
| Closed | -$102M |
|
63
Atlassian
TEAM
$37.8B
| – | – |
-26,440
| Closed | -$4.68M |
|
64
Workday
WDAY
$44.4B
| – | – |
-19,702
| Closed | -$4.4M |
|
|
X
65
PUT
DELISTED
US Steel
X
| – | – |
-500,000
| Closed | -$18.9M |
|
|
GRAL
66
GRAIL Inc
GRAL
$3.1B
| – | – |
-275,087
| Closed | -$4.23M |
|
|
TELL
67
DELISTED
Tellurian Inc.
TELL
| – | – |
-8,154,956
| Closed | -$5.65M |
|
|
CERE
68
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-1,099,229
| Closed | -$44.9M |
|
Similar funds
WA
GA
AG
CT
SVCP
EFM
PIM
MIM
Melqart Asset Management's Q3 2024 Portfolio in Review
As of Q3 2024, Melqart Asset Management held 68 positions worth $1.11B, down 8.5% from $1.21B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Melqart Asset Management withdrew a net $144M in Q3 2024, closing 17 positions and reducing 27 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $44.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Melqart Asset Management opened a new position in Smurfit Westrock worth $35.7M.
- Melqart Asset Management's largest Q3 2024 buy was Smurfit Westrock: 721,736 shares worth $35.7M.
- Melqart Asset Management added most to CATALENT, INC. in Q3 2024, an estimated $37.4M increase.
- Melqart Asset Management's biggest Q3 2024 reduction was Cytokinetics, cutting an estimated $25.8M.
- Melqart Asset Management fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $44.9M.
- Melqart Asset Management's ten largest holdings make up 55% of its $1.11B portfolio in Q3 2024.
- Melqart Asset Management opened 14 new positions and closed 17 in Q3 2024.
- Melqart Asset Management's portfolio value fell 8.5% quarter-over-quarter to $1.11B.
Based on Melqart Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.